| Code | CSB-RA011661MB8HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Rademikibart, targeting the interleukin-4 receptor (IL4R). IL4R is a type I transmembrane protein that serves as a component of receptor complexes for both IL-4 and IL-13, two critical cytokines in type 2 inflammatory responses. Upon ligand binding, IL4R initiates JAK-STAT signaling pathways that regulate immune cell differentiation, IgE production, and the expression of inflammatory mediators. Dysregulated IL4R signaling plays a central role in allergic diseases, atopic dermatitis, asthma, and various type 2 inflammatory conditions.
Rademikibart is a therapeutic monoclonal antibody designed to block IL4R signaling by preventing IL-4 and IL-13 from binding to their receptor complexes. This biosimilar antibody provides researchers with a valuable tool for investigating IL4R-mediated pathways, studying type 2 immunity mechanisms, and exploring therapeutic interventions for allergic and inflammatory disorders. It supports investigations into cytokine receptor biology, immune regulation, and the development of targeted immunomodulatory strategies.
There are currently no reviews for this product.